Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia

It remains unclear in adult acute myeloid leukemia (AML) whether leukemic expression of CD33, the target antigen for Gemtuzumab Ozogamicin (GO), add prognostic information on GO effectiveness at different doses. CD33 expression quantified in 1583 patients recruited to UK-NCRI-AML17 (younger adults)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Principais autores: Khan, Naeem, Hills, Robert K, Virgo, Paul, Couzens, Stephen, Clark, Nithiya, Gilkes, Amanda, Richardson, Peter, Knapper, Steven, Grimwade, David, Russell, Nigel H, Burnett, Alan K, Freeman, Sylvie D
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5419583/
https://ncbi.nlm.nih.gov/pubmed/27795558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.309
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados